MedPath

Ono Pharma USA, Inc.

🇺🇸United States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://www.ono-usa.com

Clinical Trials

21

Active:0
Completed:18

Trial Phases

2 Phases

Phase 1:9
Phase 2:12

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (21 trials with phase data)• Click on a phase to view related trials

Phase 2
12 (57.1%)
Phase 1
9 (42.9%)

Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

Phase 2
Terminated
Conditions
Irritable Bowel Syndrome (IBS)
Interventions
Drug: Placebo comparator
First Posted Date
2013-06-26
Last Posted Date
2016-02-25
Lead Sponsor
Ono Pharma USA Inc
Target Recruit Count
39
Registration Number
NCT01887002
Locations
🇺🇸

Boston Clinical Site, Boston, Massachusetts, United States

🇺🇸

St. Louis Clinical Site, St. Louis, Missouri, United States

🇺🇸

Chapel Hill Clinical Site, Chapel Hill, North Carolina, United States

and more 1 locations

A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

Phase 2
Completed
Conditions
Irritable Bowel Syndrome (IBS)
Interventions
First Posted Date
2013-05-01
Last Posted Date
2016-04-15
Lead Sponsor
Ono Pharma USA Inc
Target Recruit Count
200
Registration Number
NCT01844180
Locations
🇺🇸

Anniston Clinical Site, Anniston, Alabama, United States

🇺🇸

Goodyear Clinical Site, Goodyear, Arizona, United States

🇺🇸

Tucson Clinical Site, Tucson, Arizona, United States

and more 45 locations

An Open-label, Single-dose, Intravenous Administration Study of ONO-2745/CNS 7056 in Subjects With Chronic Hepatic Impairment

Phase 1
Completed
Conditions
Healthy
Hepatic Impairment
Interventions
Drug: ONO-2745 /CNS 7056
First Posted Date
2013-02-13
Last Posted Date
2013-12-03
Lead Sponsor
Ono Pharma USA Inc
Target Recruit Count
20
Registration Number
NCT01790607
Locations
🇺🇸

Anaheim Clinical Site, Anaheim, California, United States

🇺🇸

Orlando Clinical Site, Orlando, Florida, United States

🇺🇸

South Miami Clinical Site, South Miami, Florida, United States

Single and Multiple Dose Escalation and Two-sequence Crossover Study of ONO-9054 in Patients With Ocular Hypertension or Mild Open-angle Glaucoma

Phase 1
Completed
Conditions
Ocular Hypertension (OHT)
Mild Open Angle-glaucoma (OAG)
Interventions
Drug: Placebo
First Posted Date
2012-08-22
Last Posted Date
2013-06-03
Lead Sponsor
Ono Pharma USA Inc
Target Recruit Count
60
Registration Number
NCT01670266
Locations
🇺🇸

Costa Mesa Clinical Site, Costa Mesa, California, United States

🇺🇸

Newport Beach (satellite site), Newport Beach, California, United States

🇺🇸

Santa Ana (satellite site), Santa Ana, California, United States

ONO-2952 Single-dose PET Study in Healthy Adult Subjects

Phase 1
Completed
Conditions
Healthy Adult Subjects
Interventions
First Posted Date
2012-06-07
Last Posted Date
2013-06-03
Lead Sponsor
Ono Pharma USA Inc
Target Recruit Count
16
Registration Number
NCT01613703
Locations
🇺🇸

Pittsburgh Clinical Site, Pittsburgh, Pennsylvania, United States

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.